Pfizer may soon play pharmaceutical musical chairs by relocating some of its overseas drug production back to the U.S., responding to the tariff tango initiated by President Trump. Pfizer CEO Albert ...
StockWatch: Biopharma Funds Tumble with Wall Street as Industry Spared from Worst of Tariffs—for Now
President Donald Trump’s exemption of pharmaceuticals from “reciprocal” tariffs limited the declines of biopharma stocks as ...
When some of America’s most-influential CEOs were asked recently how much the stock market would need to fall before they ...
The city’s pharma giants avoided much of the initial turbulence felt by the rest of the economy in the wake of President ...
President Trump wants to bring pharmaceutical manufacturing back to the United States. Experts warn that tariffs could result ...
Pharma’s reprieve from Donald Trump’s tariffs is expected to be temporary, with Leerink analysts anticipating possible sector ...
Buying stock in great companies when they are dealing with some short-term issue that creates stock price weakness can set ...
Over the last two months, the pharmaceutical industry has remained on the sidelines as Health and Human Services Secretary Robert F. Kennedy Jr. and Elon Musk’s Department of Government Efficiency ...
With concerns mounting and speculation swirling, the particulars of President Donald Trump’s much-touted “Liberation Day” ...
Institutional Shareholder Services has recommended Pfizer investors reject a proposal on executive compensation at its ...
A group of powerful business leaders gathered to meet with Commerce Secretary Howard Lutnick in late February, seeking ...
(Reuters) -Institutional Shareholder Services has recommended Pfizer investors reject a proposal on executive compensation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback